• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Portugal Pharmaceuticals and Healthcare Report Q1 2013 - Product Image

Portugal Pharmaceuticals and Healthcare Report Q1 2013

  • ID: 2372985
  • January 2013
  • Region: Portugal
  • 91 pages
  • Business Monitor International

FEATURED COMPANIES

  • Bial
  • Bluepharma
  • Company Profiles
  • Hovione
  • Medinfar
  • MORE

BMI View:

Portugal's pharmaceutical and healthcare sector has been transformed since the intervention of the EU, IMF and ECB as part of the country's EUR78bn economic rescue package approved in May 2011. The latest review states that Portugal has already made considerable savings in the healthcare sectors, with changes such as the introduction of e-prescriptions and prescribing by active ingredients,
changes to reference pricing, reductions in pharmacy margins and price cuts just some of the measures in place. The impact on the market has been widespread. Spending has been slashed and both domestic and multinational pharmaceutical firms have seen their profits shrink. Data recently published by Infarmed show that Portugal has dropped from hosting 138 clinical trials in 2008 to just 87 in 2011, suggesting the country is losing its appeal as a location for research and development (R&D). Drug shortages in pharmacies are also commonplace, with a study published by Apifarma in October 2012 suggesting that parallel exports are partly to blame.

Headline Expenditure Projections:

- Pharmaceuticals: EUR4.47bn (US$6.21bn) in 2011 to EUR4.24bn (US$5.39bn) in 2012; READ MORE >

Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Bial
  • Bluepharma
  • Company Profiles
  • Hovione
  • Medinfar
  • MORE

Executive Summary 5

SWOT Analysis 7

Portugal Pharmaceuticals And Healthcare Industry SWOT 7

Portugal Political SWOT 8

Portugal Economic SWOT 8

Portugal Business Environment SWOT 9

Pharmaceutical Risk/Reward Ratings 10
Table: Western Europe Pharmaceutical Risk/Reward Ratings, Q113 10

Rewards 11

Risks 11

Portugal - Market Summary 13

Regulatory Regime 15

Parallel Imports 17

Recent EU Regulatory Developments 18

Pricing Regime 19

Patented Products 20

Generic Drugs 21

OTC Medicines 22

Reimbursement Regime 23

Pharmacoeconomics 24

Industry Trends and Developments 25

Epidemiology 25

Healthcare System 27

Hospital Infrastructure And Services 28

Outpatient Infrastructure And Services 29

Pharmaceutical Industry 30

Company Developments 30

Wholesale Sector 32

Pharmacy Sector 32

Clinical Research 35

Medical Devices 36

Industry Forecast Scenario 38

Overall Market Forecast 38
Table: Pharmaceutical Sales Indicators 2008-2016 40

Key Growth Factors - Industry 41
Table: Healthcare Expenditure Indicators 2008-2016 43
Table: Healthcare Governmental Indicators 2008-2016 43
Table: Healthcare Private Indicators 2008-2016 44
Table: Portugal - Economic Activity 49

Prescription Drug Market Forecast 51
Table: Prescription Drug Sales Indicators 2008-2016 52

Patented Drug Market Forecast 53
Table: Patented Drug Market Indicators 2008-2016 55

Generic Drug Market Forecast 56
Table: Generic Drug Sales Indicators 2008-2016 58
Table: Top Generic Drugs By Value In 2011 59
Table: Average Price Of Top Generic Drugs By Value 2010-2011 59

OTC Medicine Market Forecast 60
Table: OTC Medicine Sales Indicators 2008-2016 61
Table: OTC Sales Outside Of Pharmacies By Therapeutic Group (Jan-June 2012) 62
Table: OTC Sales Outside Of Pharmacies By District (Jan-June 2012) 62
Table: OTC Sales Outside Of Pharmacies By Sales Outlet (Jan-June 2012) 63
Table: Portugal OTC Sales Outside Of Pharmacies By Active Ingredient (Jan-June 2012) 63

Pharmaceutical Trade Forecast 64
Table: Exports and Imports Indicators 2008-2016 65

Other Healthcare Data Forecasts 67

Key Risks To BMI's Forecasts 67

Competitive Landscape 68
Table: Number Of Pharmaceutical Companies, Wholesalers, Pharmacies, Pharmacy Extensions And Drug Stores In Portugal 69

Company Profiles 70

Hovione 70

Bial 74

Medinfar 77

Bluepharma 79

Demographic Outlook 81
Table: Population By Age Group, 1990-2020 ('000) 82
Table: Population By Age Group, 1990-2020 (% of total) 82
Table: Key Population Ratios, 1990-2020 83
Table: Rural And Urban Population, 1990-2020 84

Glossary 85

BMI Methodology 87

How We Generate Our Pharmaceutical Industry Forecasts 87

Pharmaceuticals Business Environment Ratings 88

Risk/Reward Ratings Methodology 88

Ratings Overview 88
Table: Pharmaceutical Business Environment Indicators 89

Weighting 90
Table: Weighting Of Components 90

Sources 90

Note: Product cover images may vary from those shown

Company Profiles
Hovione
Bial
Medinfar
Bluepharma

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos